Literature DB >> 19438919

A possible role of ID-Migraine in the emergency department: study of an emergency department out-patient population.

C Mostardini1, V C d'Agostino, D E Dugoni, R Cerbo.   

Abstract

Headache symptoms account for 1-3% of admissions to an emergency department (ED). Most patients affected by a primary headache (PH) have migraine, although they are often misdiagnosed as 'headache not otherwise specified'. We investigated the possibility of using ID-Migraine (ID-M) to improve migraine recognition in the ED setting. We planned a pilot study involving ED out-patients with a diagnosis of PH. Diagnoses of a blinded headache expert were subsequently matched with the ID-M results. We tested ID-M on 230 patients (199 PH, 31 secondary headaches). Considering only PH, ID-M exhibited a sensitivity of 0.94 and specificity of 0.83 with a positive predictive value (PPV) of 0.99. The ID-M is a simple migraine screener with high sensitivity, high specificity and high PPV, even in an ED-derived population. Methodical use of this tool in an ED setting may, once a secondary headache has been excluded, lead to rapid diagnosis of migraine.

Entities:  

Mesh:

Year:  2009        PMID: 19438919     DOI: 10.1111/j.1468-2982.2009.01889.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  3 in total

1.  The use of ID migraine™ questionnaire in patients with multiple sclerosis.

Authors:  Veronica Villani; Luca Prosperini; Carlo Pozzilli; Marco Salvetti; Alessandro Ciuffoli; Giuliano Sette
Journal:  Neurol Sci       Date:  2010-11-11       Impact factor: 3.307

2.  Validation of the "My Headache Checker" that includes osmophobia in the diagnosis of migraine.

Authors:  Masahide Matsushita; Kaori Matsumoto; Satoko Kitamura; Naoki Komatsu; Hiromi Seo; Seisho Takeuchi
Journal:  J Gen Fam Med       Date:  2020-09-03

3.  Diagnostic and classification tools for chronic headache disorders: A systematic review.

Authors:  Rachel Potter; Katrin Probyn; Celia Bernstein; Tamar Pincus; Martin Underwood; Manjit Matharu
Journal:  Cephalalgia       Date:  2018-10-18       Impact factor: 6.292

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.